Roughly 1 in 3 adults has metabolic dysfunction–associated steatotic liver disease, or MASLD. A doctor outlines how to detect and slow the condition early.

Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

The share price of Danish pharmaceutical giant Novo Nordisk ( NVO +1.31%) hit a four-year low Monday, falling below $44 a ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Inflammation likely plays a key role in T2D outcomes, and various anti-inflammatory treatments may improve both T2D and its ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...